Platelet Rich Plasma Combined With Human Umbilical Cord Mesenchymal Stem Cells for Stage 3 and 4 Stress Injury
This study is an open-label, single-center trial which aim to evaluate of efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) combined with platelet-rich plasma (PRP) in stage 3 and 4 stress injury.
- EligibilityCriteria: Inclusion Criteria:  18-80 years old, regardless of gender; Patients with stage 3 and stage 4 pressure injuries (According to National Pressure Ulcer Advisory Panel (NPUAP)/European Pressure Ulcer Advisory Panel (EPUAP) classification system for pressure ulcers); There were no complications affecting the wound healing; After through debridement for the first time, the wound volume meets the requirement of "10-100cm3"; Platelet count before treatment 100~300×109/L; The patient voluntarily participates and signs an informed consent form.  Exclusion Criteria:  Individuals with coagulation dysfunction or hemorrhagic diseases; People with skin diseases, diabetes and immune diseases; Individuals with mental or psychological disorders; Individuals with allergies to multiple drugs; Pregnant or lactating women; Those who need to take medication that affects platelet and coagulation function for a long time or in the near future, but have not stopped taking medication within the past week. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult